NAUT - Nautilus initiated as a buy at Jefferies on protein profiling technologies; sees 30% upside

ermess/iStock via Getty Images Jefferies has initiated shares of Nautilus ([[NAUT]] -0.4%) with a buy rating and $13 price target (~30% upside) as the early-stage life sciences tools company's platform focuses on analyzing the human proteome. Analyst Brandon Couillard writes that the company's protein profiling platform could help usher in a new era of personalized and predictive medicine. Couillard says that the total addressable market Nautilus operates in could surpass $25B in the future. He adds that Nautilus has more than $300M in cash to support an expected launch of the platform in 2H 2023.

For further details see:

Nautilus initiated as a buy at Jefferies on protein profiling technologies; sees 30% upside